This comprehensive investor profile synthesizes the operational, strategic, and financial data for **Titan Biotech Limited**, a prominent player in the Indian biotechnology landscape. ### Diversified Product Ecosystem and Industry Applications Titan Biotech Limited (operating under the brand **TM Media**) is a leading Indian manufacturer and exporter of biological products. The company specializes in high-growth biotechnology segments, focusing on fermentation and protein-based ingredients. Its portfolio serves a global market valued at **USD 5.46 Billion** in **2024**, with a projected **CAGR of 8.82%**. The company’s core offerings include: * **Biological Extracts:** Peptones, Protein Hydrolysates, Yeast Extract, Malt Extract, Liver Extract, and Bile Extract. * **Microbiology & Diagnostics:** Dehydrated Culture Media, Prepared/Ready-to-Use (RTU) Culture Media (including **Petri dishes**), Chromogenic Media, Supplements, and Antibiotic Discs. * **Agriculture:** Plant Growth Promoters, Bio-Fertilizers, Bio-pesticides, and Soil Nutrition ingredients. * **Other Segments:** Laboratory Chemicals, Plant Tissue Culture Media, and Food Additives (**FSSAI certified**). **Primary Industry Verticals:** * **Clinical Microbiology:** Pathogen identification in hospitals and diagnostic laboratories. * **Industrial Microbiology:** Quality control in **Pharmaceuticals, Food & Beverages, and Biotechnology**. * **Research & Academia:** Studies in microbial diversity and **Environmental Biotechnology**. --- ### Manufacturing Infrastructure and Operational Efficiency The company operates **three** specialized manufacturing units located in the RIICO Industrial Area, Rajasthan. Titan Biotech emphasizes resource optimization to maintain cost competitiveness and minimize environmental impact. | Facility | Location | Focus Area | | :--- | :--- | :--- | | **Plant I** | A-902 A, Phase-III, Bhiwadi | Registered Office & Primary Biological Production | | **Plant II** | E 539-540, Chopanki, Bhiwadi | Industrial Production & Bulk Division | | **Plant III** | F 689-690, Chopanki, Bhiwadi | Media Division & Capacity Expansion | **Resource Consumption Metrics:** The company has demonstrated improved efficiency in energy and fuel consumption per unit of production: * **Electricity:** Reduced from **9.53 Units/kg** to **9.46 Units/kg** (FY 2024-25). * **Bio Briquettes:** Reduced from **7,097.86 Units/ton** to **6,906.32 Units/ton**. * **PNG Gas:** Reduced from **66.16 Unit/kg** to **62.84 Unit/kg**. --- ### Financial Performance and Shareholder Value Titan Biotech operates a single primary business segment: **Biological Products**. It maintains a strong export orientation and a consistent track record of profitability. **Consolidated Financial Summary:** | Particulars | FY 2024-25 (₹ Lakhs) | FY 2023-24 (₹ Lakhs) | FY 2022-23 (₹ Lakhs) | | :--- | :--- | :--- | :--- | | **Total Revenue** | **16,036.33** | **16,582.03** | **14,594.24** | | **Profit After Tax (PAT)** | **1,827.11** | **2,366.32** | **2,102.48** | | **EBITDA Margin** | **21.72%** | **21.72%** | - | | **Domestic Sales** | **10,255.00** | **10,757.81** | **9,979.85** | | **Overseas Sales** | **5,390.00** | **5,649.40** | **4,420.08** | **Capital Structure and Liquidity Initiatives:** * **Stock Split:** To encourage retail participation, the company executed a **1:5 sub-division** (Record Date: **February 20, 2026**), splitting **₹10** shares into **₹2** shares. * **Dividend:** A dividend of **₹2.00 per equity share** was recommended for FY 2024-25. * **Cash Position:** Held **₹5.13 Crore** in cash and equivalents as of March 31, 2025. * **Dematerialization:** **96.963%** of equity shares are held in demat form; physical shareholding has been reduced by **70.70%** over the last six years. --- ### Strategic Investments and Subsidiary Expansion Titan Biotech is aggressively expanding its influence through its associate companies, **Peptech Biosciences Limited** and **Titan Media Limited**. * **Titan Media Limited Stake:** The company has significantly increased its voting rights in Titan Media from **32.29%** to **48.44%** in 2025. Through a committed rights issue of **3,390,510** shares, the company targets an eventual **64.58%** ownership. * **Leadership Continuity:** Managing Directors **Mr. Naresh Kumar Singla** and **Mr. Suresh Chand Singla** have been re-appointed for five-year terms (2026–2031). **Mr. Shivom Singla** was appointed Whole Time Director in 2023. --- ### Research, Development, and Future Outlook The company aligns its growth with the projected **$300 Billion** Indian bio-economy by 2030. * **In-house Innovation:** Titan Biotech relies on proprietary technology; **no technology has been imported** in the last **5 years**. * **R&D Priorities:** Current activities focus on **Energy Conservation**, **Pollution Control**, and developing new products for the **Health Supplement** and **Antimicrobial Resistance** markets. * **Certifications:** The company maintains **ISO 9001:2015, ISO 22000, FSSC 22000, GMP, and FSSAI** certifications to ensure global compliance. * **Macro Drivers:** Leveraging government initiatives like **Aatmanirbhar Bharat** and the **GOBARdhan** scheme, alongside the Department of Biotechnology’s **₹2,251.52 Crore** budget allocation. --- ### Risk Profile and Mitigation Strategies The company manages risks through the Board and Audit Committee, categorizing threats across strategic and financial domains. | Risk Category | Description & Mitigation | | :--- | :--- | | **Market & Competition** | Intense competition from global players with larger resources. Mitigation: Focus on **high-yield in-house technology** and cost efficiency. | | **Raw Material Volatility** | Price increases can impact margins. Mitigation: Process improvements and **energy optimization** to offset costs. | | **Foreign Exchange** | Exposure from exports (**₹52.95 Crore** earnings). The company **does not currently hedge** receivables. | | **Regulatory Compliance** | Stringent global standards and audit requirements. Mitigation: Upgrading ERP to **Microsoft Navision Business Enterprise** for enhanced **audit trail** features. | | **Product Safety** | Risks of contamination (e.g., *E. coli*). Mitigation: Strict adherence to **GMP** and **ISO** quality protocols. |